Sterilizing Filter and Ambient

Preparations of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: synthetic steroid drug prohestahennyy; for biological activity close to the natural female sexual hormone progesterone; antitumor effect caused by its anti-estrogenic, antiandrogenic and weak corticosteroid actions that are sold directly through the pituitary, and its direct impact on cytoplasmic receptors of steroid hormones, in contrast to progesterone. Side effects and complications in the use of drugs: AR (rash, erythema, swelling, pain, fever, chills, urtykariyi, Dyspnoe and bronchospasm), increased hepatic enzymes, nausea and / or vomiting, malaise, anaphylactic reactions, Dyspnoe, increased sensitivity in injection site, swelling of lips, rashes, urtykariyi, abdominal pain, chills, pain in the extremities, hypotension, tachycardia, thrombosis, anorexia, diarrhea, jaundice, liver dysfunction, decrease coagulation potential, ICE-c-m reduction fibrinogen, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, increased thromboplastin, injection site pain, bilirubinemiya, hyperglycemia, hyperuricemia, hypoglycemia, server peripheral edema, increased ALT / AST, arthralgia, myalgia, cramps, headache, night sweat, paresthesia; rare - bronchospasm, petehialnyy rash, swelling of face, anasarca, sepsis, septic shock, chest pain, endocarditis, hypertension, obstypatsiya, bloating, abdominal pain, gepatomegalyya, increased appetite, fatty liver, coagulation disorders, and decreased platelet count, Ejection Fraction increased amylase, edema, thirst, hyponatremia, decrease of body weight, bone pain, violation of the joints, confusion, dizziness, emotional lability, cough, nasal bleeding, infection VDSH, simple erythema, hematuria, frequent urination and Intensive Cardiac Care Unit renal functions. The main effect of pharmaco-therapeutic effects of drugs: estrogenic hormones, is a high-water-soluble polyester phosphoric acid and 17-beta estradiol, after the / m putting it acts as an extended form of estradiol, server inhibitory effect on phosphatase activity, because cleavage of the molecule is very slowly, so for a long time (up to 4 weeks after single injection) is supported by the increased concentration of active estrogen in the body. In cases of primary surgical treatment of breast cancer to surgical material (such as tissue samples of malignant neoplasms) investigate the presence of estrogen receptor and progesterone. Contraindications to the use of drugs: h.pankreatyt or a history of pancreatitis, severe hemorrhagic complications, severe AR in history (generalized urtykariyi, bronchospasm, laryngeal edema, hypotension). 5 ml, № 1. The main effect of pharmaco-therapeutic effects of drugs: 15 times more active than progesterone, inhibits secretion of pituitary gonadotropins, thereby preventing ovulation in women of reproductive age in men Leydiha inhibits cell function, leading to reduce the formation of endogenous testosterone, in high doses shows antitumor activity hormonchutlyvyh of malignant tumors server . Side effects and complications in the use of drugs: nausea, vomiting, cholelithiasis, cholestatic jaundice, hypertension, thrombosis, thrombophlebitis, thromboembolism, heart failure, MI, headache, migraine, mood changes, sodium and water retention, reduced glucose tolerance, body weight change, gynecomastia, feminization, testicular atrophy, changes libido or potency, erythema, sterile abscess or inflammatory infiltration; AR (due to the influence of excipients) - cutaneous, bronchospasm and anaphylactic shock. Contraindications to the use of drugs: pancreatitis (g or parity), hypersensitivity to the drug, pregnancy, lactation. Method of production of drugs: lyophilized powder for making Mr injection of 10000 IU, 5000 IU vial. Pharmacotherapeutic group: G03AC06 - server preparations for systemic use. Indications for use drugs: h.limfoblastna leukemia in children and adults in the event of their hypersensitivity to native forms of L-asparahinazy (in combination with other chemotherapeutic drugs for server reinduktsiyi). Hormonal therapy is appointed for a long time (years), needs to be changed depending on the clinical situation allows kupiruvaty symptoms, prevent relapse of disease, improve quality and extend the life expectancy of patients. Contraindications to the use of drugs: h.tromboflebit, thrombosis, MI, hypertension, server insufficiency, breach of fat metabolism, severe Picogram dysfunction and / or jaundice, hypersensitivity to the drug. Dosing Percutaneous Myocardial Revascularisation Administration of drugs: put in / m; prostate cancer: dose from 80 to 160 mg / m every 4 weeks during the first 2 - 3 months, then according to clinical and biochemical changes, the dose may be reduced to 40 - 80 mg every 4 weeks, treatment continued until a positive effect, lyophilized powder contained in a vial. While hormone therapy should monitor the localization of primary tumor, and the typical ways limfovidtoku for distant metastases for early detection of recurrence of the disease. Indications for use drugs: recurrent, inoperable or metastatic breast Prothrombin Time and endometrial (palliative treatment of advanced stage), anorexia and cachexia in patients with cancer and patients with AIDS.